Biotech · Private company · Dallas, TX, US
Forte Biosciences, Inc.
SEC CIK 0001419041
Track this companyFree. Adds Forte Biosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials20 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- FB-401Phase 2 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 StudyPHASE2 · TERMINATED · started Jun 2, 2021ClinicalTrials.gov NCT04936113 · fetched Nov 12, 2026
- Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic DermatitisPHASE2 · COMPLETED · started Oct 13, 2020ClinicalTrials.gov NCT04504279 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Aug 27, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 1, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 14, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 14, 2025 · fetched Nov 12, 2026